相关临床试验
400
117 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1907
已完成
192
48.0%
尚未招募
117
29.3%
招募中
79
19.8%
暂停
2
0.5%
Unknown
3
0.8%
暂无批准数据
- Researchers used AlphaFold to design IDP1, a biodegradable protein coating that extended nanoparticle circulation time more than fourfold compared to PEG in mouse models. - An ultra-thin rigid endoscope fitting inside a 16-gauge needle delivers laser light directly into tumors, using 28% less power while maintaining efficacy. - In colon cancer-bearing mice, a single dose of IDP1-coated nanoparticles plus one laser treatment eliminated tumors within 14 days with no recurrence over 40 days. - The team plans safety studies and will test the platform in head and neck, esophageal, and pancreatic cancers reachable by endoscope.
- Researchers at Tohoku University discovered that oral drug MA-5 can improve both heart and muscle problems in Barth syndrome, a rare genetic disorder affecting 1 in 300,000 births worldwide. - MA-5 boosted cellular energy production by up to 50% and protected cells from oxidative stress-induced death by enhancing interactions between mitochondrial proteins mitofilin and ATP synthase. - The drug dramatically improved climbing ability and normalized elevated heart rates in Drosophila models, while correcting abnormal mitochondrial structures in human muscle cells derived from patient iPS cells. - Phase I clinical trials in Japan have been completed successfully, with Phase II trials being prepared, making MA-5 the first oral medication for Barth syndrome to progress to clinical trial stage.
